Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.

Authors

• William Kelly

Publication/Presentation Date

5-2023

Volume

41

Issue

16

Published In/Presented At

DOI: 10.1200/JCO.2023.41.16_suppl.5087

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article